Vanguard's Model Evolves
Vanguard's founders believed they could pick preclinical compounds destined to become successful drugs and develop them cost-effectively with a virtual organization using CROs. To get access to other companies' compounds, Vanguard agrees to fund development--and to give the originator the option to reacquire the drug for marketing. But the original model's weaknesses--high risk, high cost, and perhaps not so high a return--have become apparent. Vanguard's trying to adjust the model appropriately.
You may also be interested in...
Just three years after its founding, Chinese cell therapy developer IASO Bio already has two assets in clinical development and the Nanjing firm has recently attracted $60m in financing. In an exclusive interview, its R&D head told Scrip that speed and partnerships are propelling Chinese developers on a trajectory to quickly catch up with the west in the emerging cell-therapy arena.
Updated guidance from England’s National Institute for Health and Care Excellence says two neurostimulation systems for treatment-resistant depression and epilepsy should only be used under special conditions. See what LivaNova’s VP of difficult-to-treat depression, Jonathan Walker, said about it here.